Gsk Share Discussion Threads

[geckotheglorious] 27/4/2022 13:56

GlaxoSmithKline plc 2022 Q1 - Results - Earnings Call Presentation


Of interest to some.

[tradermichael] 27/4/2022 13:21

Listened to Emma's Presentation of Results earlier today. As usual, lots of erms, ums, errs, etc. (- she's a terrible speaker). However, the results talk volumes.

[tradermichael] 27/4/2022 08:25

Results far exceeded expectations, looking good for the 'split' .... ;0)

[tradermichael] 27/4/2022 07:16

GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER;
Total EPS 35.9p +67% AER, +66% CER and Adjusted EPS 32.8p +43% AER, +43% CER

[tradermichael] 27/4/2022 07:12

Very strong results today .... ;0)

[waldron] 27/4/2022 07:09

GlaxoSmithKline PLC on Wednesday posted higher earnings and revenue for the first quarter, beating expectations as sales rose across the biopharma and consumer healthcare businesses.

Net profit at the British pharmaceutical major came in at 1.80 billion pounds ($2.26 billion) for the quarter, up from GBP1.07 billion in the same quarter a year prior. Revenue grew to GBP9.78 billion compared with GBP7.41 billion in the first quarter of 2021. A company-provided consensus had seen net profit clocking in at GBP1.51 billion and revenue at GBP9.15 billion.

Earnings per share were 35.6 pence in the quarter, a jump from 21.3 pence in the same quarter the year prior. Adjusted earnings per share--a closely-watched metric--were 32.8 pence, which the company said is 43% higher than the year prior.

Glaxo confirmed its guidance for 2022, saying it expects to deliver sales growth of between 5% and 7% at constant exchange rates, and adjusted operating profit growth of between 12% and 14% at constant exchange rates. The guidance excludes contribution from Covid-19 solutions, the company said.

It reiterated that it is on track to demerge and list its consumer-healthcare business, named Haleon, in July.



Write to Cecilia Butini at [e-mail]



(END) Dow Jones Newswires

April 27, 2022 02:40 ET (06:40 GMT)

[mister md] 27/4/2022 06:47

results seem great

'boring' FTSE value stocks the place to be imho

[spyder] 27/4/2022 06:35

Great results, beating analysts expectations. Hopefully building some good momentum here.
GSK should look appealing to investors who have in the last few days pulled funds out of overpriced IT growth stocks.

[kennewil] 27/4/2022 06:19

Should go down well.

[tradermichael] 26/4/2022 10:53

Last February, the company said sales in 2022, after the consumer unit spin-off, were expected to grow 5% to 7% and adjusted operating profit was forecast to rise 12% to 14%.

Wednesday's results should give:
1. An indicator of how close to these projected (good) figures the company is performing
2. Fuller detail on the 'split'.
3. Further infromation on future dividends:GSK expects to declare a 27p per share dividend payable by the current group for the first half of 2022. This comprises 22 pence per share for new GSK and 5 pence per share representing Consumer Healthcare during the first half whilst part of the group. For the second half of 2022, new GSK continues to expect to declare a 22p per share dividend. As previously communicated, new GSK would expect to declare a dividend of 45 pence per share for 2023.

[alibizzle] 25/4/2022 23:45

Thanks I bought over 2000 shares

[netcurtains] 25/4/2022 12:52

#FTSE100 its worth remembering that 5m young working age refugees entering the EU from Ukraine is actually an economic stimulus to the EU. Its another 5m consumers all spending about 30k a year, and the associate economic multiplier effect on the original sum. Its big money.

[waldron] 23/4/2022 20:15

In theory you could sell on the 20th but perhaps to avoid any hiccups and end of week sell off perhaps sell on Monday 23rd May

THE CHOICE IS YOURS

[alibizzle] 23/4/2022 18:52

Thanks so if I buy on the 18th when can I sell to be sure to get my.dividend ? Thank you .

[waldron] 23/4/2022 14:45

Dividend calendar

Details of our dividend timetable by quarter.

Dividend timetable for Q1 2022

Announcement date Wednesday 27 April 2022

Ex-dividend date* Thursday 19 May 2022

Record date Friday 20 May 2022

Last date for DRIP elections Thursday 16 June 2022

Payable Thursday 7 July 2022


BUY BEFORE EX DIVI DATE

YOUR LAST BUY DATE TO GET DIVI Wednesday 18 May 2022

[alibizzle] 23/4/2022 07:39

Hi there if I invest before record day will I get my dividend ? Something about ex dividend date ? They are only one day apart so can I buy and sell in 3 days and get my dividend ? Sorry for asking just confused . Also is it worth buying on Monday before the Divi announcement next wed or will share price be expected to fall then ? Thank you

[alphorn] 22/4/2022 08:46

Hi Dud, some bad numbers out this morning and GBP hit which should benefit Big Pharma. I have little in the market at present, in some boring utilities etc. I am very bearish. In so far as GSK is concerned the split should give some short term gain and may (likely?) attract predators, particularity with a cheaper currency.
I have closed my GSK positions for now. DYOR etc.

[dudishes] 22/4/2022 08:00

Alphorn,

Whilst making large gains dot/com, I did admit to losses.

Eye off the ball, I lost £24K RTD (Retail Decisions).

I was warned by a colleague but ignored, my mistake.

Lesson learnt.

GSK/AZN both dipping, should I stay or should I go?

Mindset at the moment is take divvies in May and move on?

Your thoughts always appreciated.

cheers

[netcurtains] 22/4/2022 07:36

The weak pound good for U.K. dollar earners, who report in dollars, bigger dividends when converted into sterling.

[geckotheglorious] 21/4/2022 11:52

GSK/CureVac second gen COVID-19 shot shows promise against Omicron in mouse study

CureVac (NASDAQ:CVAC) shares are trading higher in the pre-market Thursday after the German biotech announced promising pre-clinical data for a second-generation bivalent COVID-19 vaccine candidate it jointly develops with GlaxoSmithKline (NYSE:GSK).
In the study, the animals were immunized on day 0 and day 28 with a 0.5 µg dose of the monovalent second-generation vaccine candidate or with a 0.5 µg dose of the bivalent vaccine candidate combining two mRNAs encoding for the Beta and the Delta variant.
According to the company, the experimental bivalent candidate “significantly reduced” the virus level of mice upon exposure to either variant on day 56.

Notably, the bivalent vaccine candidate is found to have led to twofold higher virus neutralizing antibody levels against the Omicron variant compared to the levels seen against the Delta variant.
In March, CureVac (CVAC) announced the dosing initiation in a Phase 1 trial for its GSK (GSK)-partnered second gen mRNA-based COVID-19 vaccine called CV2CoV.

[grahamburn] 20/4/2022 18:56

Notice that the Dow Jones comment on the GSK/Unite pay dispute this evening provides a slightly different slant to the criticism by the Unite union mentioned in the LSE report in philanderer's post.

It includes the following:

According to the union, GlaxoSmithKline's offer for a 2.75% pay rise equals a pay cut for the workforce, given that the true rate of inflation stands at 9%. It hailed the offer as "derisory" and said the company now has 48 hours to make an improved offer, or the strike will be announced.

In response, the company said it actually offered a 4% increase in addition to a 2% one-off award and an annual bonus, and that 2.75% referred to an opening offer it made months ago.

[tradermichael] 20/4/2022 13:27

We'll know more in June 2022:


Due to its size, the demerger qualifies as a Class 1 transaction under the UK Listing Rules and so requires the approval of GSK shareholders at a general meeting. A circular is expected to be sent to GSK shareholders in connection with approval of the proposed demerger and separation in June 2022, alongside publication of a prospectus in connection with the listing of Haleon.

A shareholder vote for approval and subsequent demerger is expected in July 2022. Haleon shares are expected to attain a premium listing on the London Stock Exchange, with ADRs listed in the US.

[baddeal] 20/4/2022 11:29

Fwiw I've been in gsx since June 2000, always took divis as shares until last year and now take cash. Effective annual return of 9.4% pa valued at todays price